Singapore Markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.74+0.22 (+2.09%)
At close: 04:00PM EST
10.95 +0.21 (+1.96%)
After hours: 07:40PM EST

BioCryst Pharmaceuticals, Inc.

4505 Emperor Boulevard
Suite 200
Durham, NC 27703
United States
919 859 1302

Full-time employees358

Key executives

NameTitlePayExercisedYear born
Mr. Jon P. StonehouseCEO, Pres & Exec. Director1.14MN/A1961
Mr. Anthony J. DoyleSr. VP & CFO745.79kN/A1980
Dr. William P. Sheridan MBBSChief Devel. Officer843.42k1.89M1955
Dr. Yarlagadda S. BabuChief Discovery Officer698.33k831.93k1953
Dr. Helen M. Thackray FAAP, M.D.Chief R&D Officer966.38kN/A1968
Mr. Michael L. JonesExec. Director of Fin. & Principal Accounting OfficerN/AN/A1970
Ms. Alane P. BarnesSr. VP, Chief Legal Officer & Corp. Sec.N/AN/A1966
Mr. John D. BluthChief Communications OfficerN/AN/A1973
Ms. Stephanie AngeliniChief People OfficerN/AN/AN/A
Dr. Elliott T. BergerSr. VP of Regulatory AffairsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Corporate governance

BioCryst Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 October 2022 is 5. The pillar scores are Audit: 8; Board: 2; Shareholder rights: 8; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.